Abstract
The causal relationship between inflammation and cancer has been documented for sometime, but its molecular nature remains ill defined. Increasing evidence suggested that inflammatory microenvironment in and around tumors is an indispensable participant in the neoplastic process. High level of free radicals produced during inflammation significantly induces DNA damage while evading apoptosis, a hallmark of cancer, reduces the capability of tissues to eliminate damaged cells. Therefore, the mechanism by which inflammation affects the apoptosis pathway is crucial to understand inflammation- associated carcinogenesis. Nuclear factor-κB (NF-κB), a transcriptional factor, plays an important role in the regulation of inflammatory responses. NF-κB signaling, which can be activated by diverse stimuli including proinflammatory cytokines, infectious agents and cellular stresses, has been shown to be involved in carcinogenesis and resistance to multiple drug therapy. In this review, we focus on the role of NF-κB signaling on the apoptotic effect in inflammationassociated carcinogenesis. These insights may help us to consider the role of NF-κB in inflammation and cancer and further on as a target of drugs for the prevention and treatment of these diseases.
Keywords: Apoptosis, carcinogenesis, inflammation, NF-κB, p53
Current Cancer Drug Targets
Title: Effect of NF-κB Signaling on Apoptosis in Chronic Inflammation-Associated Carcinogenesis
Volume: 10 Issue: 6
Author(s): H. Wang and C.H. Cho
Affiliation:
Keywords: Apoptosis, carcinogenesis, inflammation, NF-κB, p53
Abstract: The causal relationship between inflammation and cancer has been documented for sometime, but its molecular nature remains ill defined. Increasing evidence suggested that inflammatory microenvironment in and around tumors is an indispensable participant in the neoplastic process. High level of free radicals produced during inflammation significantly induces DNA damage while evading apoptosis, a hallmark of cancer, reduces the capability of tissues to eliminate damaged cells. Therefore, the mechanism by which inflammation affects the apoptosis pathway is crucial to understand inflammation- associated carcinogenesis. Nuclear factor-κB (NF-κB), a transcriptional factor, plays an important role in the regulation of inflammatory responses. NF-κB signaling, which can be activated by diverse stimuli including proinflammatory cytokines, infectious agents and cellular stresses, has been shown to be involved in carcinogenesis and resistance to multiple drug therapy. In this review, we focus on the role of NF-κB signaling on the apoptotic effect in inflammationassociated carcinogenesis. These insights may help us to consider the role of NF-κB in inflammation and cancer and further on as a target of drugs for the prevention and treatment of these diseases.
Export Options
About this article
Cite this article as:
Wang H. and Cho C.H., Effect of NF-κB Signaling on Apoptosis in Chronic Inflammation-Associated Carcinogenesis, Current Cancer Drug Targets 2010; 10 (6) . https://dx.doi.org/10.2174/156800910791859425
DOI https://dx.doi.org/10.2174/156800910791859425 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Homocysteine, Intracellular Signaling and Thrombotic Disorders
Current Medicinal Chemistry Genetics of Spondyloarthropathies and Inflammatory Bowel Disease: Searching for Common Susceptibility Factors
Current Rheumatology Reviews Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry Travelers’ Diarrhea: A Clinical Review
Recent Patents on Inflammation & Allergy Drug Discovery Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design Immune-Glutamatergic Dysfunction as a Central Mechanism of the Autism Spectrum Disorders
Current Medicinal Chemistry Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy
Current Molecular Pharmacology Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Relationship Between Virulence Factors and Outcome of Ventilator-Associated Pneumonia Related to Pseudomonas aeruginosa
Current Respiratory Medicine Reviews Randomized, Placebo Controlled Study of the Effects of Etoricoxib on Markers of Inflammation, Pain and Muscle Force After Eccentric Exercise
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Hepatitis C Treatment in Patients with Drug Addiction: Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects
Current Drug Abuse Reviews Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions
Current Pharmaceutical Design